Research
Hormonal
SGLT-2 inhibitors reduce cardiovascular and renal risks in type 2 diabetes patients by promoting glucose and sodium excretion, which triggers fatty acid beta-oxidation and depletes ectopic/visceral fat.
If you have Type 2 Diabetes and heart or kidney risks, ask your doctor about SGLT-2 inhibitors. These medications not only lower blood sugar but also help reduce harmful fat around your organs, which protects your heart and kidneys.
GoodSupportsHIGH confidence
The sodium-glucose cotransporter-2 inhibitor-mediated sodium/glucose deprivation can directly improve glycemic control and kidney outcome in patients with T2DM. The glucose deprivation might also promote systemic fatty acid β-oxidation to deplete ectopic/visceral fat and thereby contribute to the prevention of cardiovascular diseases.
Why this rating
Supported by multiple major CVOTs and meta-analyses cited in the review.
Source
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes
Jingjing Zhu et al. · Current Atherosclerosis Reports · 2023
DOI 10.1007/s11883-023-01181-4
narrative_reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1RA) significantly reduce body weight and visceral fat, leading to improved cardiovascular and renal outcomes in T2DM patients.Good
- Energy-restricted diets have limited efficacy in reducing body fat and preventing cardiovascular events in T2DM compared to metabolic surgery or newer pharmacological interventions.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →